Back to Journals » OncoTargets and Therapy » Volume 8

Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era [Corrigendum]

Authors Berger JL, Smith A, Zorn KK, Sukumvanich P, Olawaiye AB, Kelley J, Krivak TC

Received 8 January 2015

Accepted for publication 8 January 2015

Published 9 March 2015 Volume 2015:8 Pages 593—594

DOI https://doi.org/10.2147/OTT.S80592

Berger JL, Smith A, Zorn KK, et al. Onco Targets Ther. 2014;7:1409–1413.

It has been brought to our attention that there are two pharmaceutical companies that market drugs with the name ‘lipodox’ and we erroneously refer to the product used in our current study-Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era. by the trade name Lipo-dox®, a drug produced by TTY Biopharm Co. Ltd, when the Sun Pharma product is Lipodox. Lipo-Dox® utilizes a different liposomal particle than Doxil®, DSCP versus HSCP. Due to the similarity of the drug names, we were under the mistaken impression that Sun Pharma’s Lipodox utilized the DSCP liposome. We postulated that this might be related to the poor clinical outcomes seen in our population. It is now clear that Lipodox utilizes the same liposome as Doxil® and this is not a relevant point of discussion. The authors would like to let the readers know that Lipodox uses HSCP as the liposome and this should be corrected in the manuscript. The patients in our current study were all treated with Lipodox, and this drug uses HSCP as the liposome.

Read the original article

A Letter to the Editor has been published for this paper

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other article by this author:

Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era

Berger JL, Smith A, Zorn KK, Sukumvanich P, Olawaiye AB, Kelley J, Krivak TC

OncoTargets and Therapy 2014, 7:1409-1413

Published Date: 8 August 2014

Readers of this article also read:

Increased serum levels of interleukin-10 predict poor prognosis in extranodal natural killer/T-cell lymphoma patients receiving asparaginase-based chemotherapy

Wang H, Wang L, Wuxiao ZJ, Huang HQ, Jiang WQ, Li ZM, Lu Y, Xia ZJ

OncoTargets and Therapy 2015, 8:2589-2599

Published Date: 14 September 2015

Companion diagnostics and molecular imaging-enhanced approaches for oncology clinical trials

Van Heertum RL, Scarimbolo R, Ford R, Berdougo E, O’Neal M

Drug Design, Development and Therapy 2015, 9:5215-5223

Published Date: 11 September 2015

Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology

Aprile G, Leone F, Giampieri R, Casagrande M, Marino D, Faloppi L, Cascinu S, Fasola G, Scartozzi M

OncoTargets and Therapy 2015, 8:1149-1156

Published Date: 22 May 2015

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Pegylated liposomal doxorubicin in the management of ovarian cancer

Gabriella Ferrandina, Giacomo Corrado, Angelo Licameli, et al

Therapeutics and Clinical Risk Management 2010, 6:463-483

Published Date: 29 September 2010

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010